Transforming growth factor beta (TGF-β) belongs to a large growth factor superfamily having an important role in a number of physiologic and pathologic states of the organism, and it binds to the cell by means of its receptors. TGF-β has an important role in proliferation of epithelium, endothelium and hematopoietic cells and cell differentiation, wound healing, inflammation, angiogenesis and tumorigenesis. Mutation of TGF-β and its receptors is essential in pathogenesis of disease, especially carcinoma. The influence of TGF-β during bone formation and remodeling has been shown throughout many researches where the respective molecule in bone fracture is noted as one of primary factors able to be detected in patients’ blood. TGF-β III receptor (TGFβrIII) is among the most present receptors participating in action of TGF-β on cells. TGFβrIII is not detected in plasma of healthy people, but it has been found in patients with long bone fracture. The aim of this study is to monitor the concentration of soluble TGFβrIII during long bone fractures in humans and to determine its possible role as a biomarker in bone healing follow up. The study involved 22 patients aged 18 and above with the diagnosis of single long bone fracture induced by trauma and 9 healthy volunteers (no skeletal trauma). Plasma samples were taken in different temporal instants beginning with moment of fracture during regular control examinations and in healthy subjects during physical examination. TGFβrIII concentration in collected samples was determined using ELISA method, and was analyzed using REML method. Concentration of soluble TGFβrIII in healthy individuals amounts to Ẋ= 40±10.7 pg/mL. Concentration of soluble TGFβrIII after fracture rises steadily, reaching plateau between week 12 and 14, and then falls slowly to its initial value at the end of week 25. This study has shown that there is expression of TGFβrIII in plasma of healthy individuals and that concentration of TGFβrIII during bone healing exhibits parabolic change. It can be concluded therefore that TGFβrIII may be considered potential biomarker for bone healing.